Document is current
Any future updates will be listed below
-
Authors
Zhou, Jingjing
Wang, Xiao
Feng, Lei
Xiao, Le
Yang, Rui
Zhu, Xuequan
Shi, Hui
Hu, Yongdong
Chen, Runsen
Boyce, Philip
Wang, Gang
-
Funding
Funding for this research was provided by:
National Key Research & Development Program of China (2016YFC1307200)
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201607)
Beijing Municipal Administration of Hospitals Incubating Program (PX2018064)
The Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151801)
The Capital's Funds for Health Improvement and Research (CFH 2018-1-2121)
- License Information
-
More Information
Article History
Received: 12 May 2020
Accepted: 3 May 2021
First Online: 19 May 2021
Declarations
:
: The study protocol was approved by the ethics committee of Beijing Anding Hospital and Beijing Chaoyang Hospital, respectively. The study was carried out according to the Declaration of Helsinki and the guidelines for good clinical practice. The trial was registered ( #NCT01824433) on April 4, 2013, prior to the study initiation. Written informed consent was obtained from all participants before the commencement of any study procedures. Patients were informed that they were free to withdraw from the trial at any time.
: Not applicable.
: Dr. Gang Wang received research support from Pfizer and Merck & Co., Inc. The other authors report no competing interests.
